Evidence map›Paper›PMID 41791709›Full record

ReviewThe Journal of biological chemistry2026

The SWI/SNF complex in tumor metabolism: Mechanisms and therapeutic implications.

Xuan-Hao Pan, Jian Wang, Jing Su, Rui Zhao, Yu-Fei Gao

Abstract readReview
In one paragraph

Review in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xuan-Hao PanDepartment of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China; Jilin Province Neuro-Oncology Engineering Laboratory, Changchun, Jilin, China; Jilin Provincial Key Laboratory of Neuro-Oncology, Changchun, Jilin, China.
Jian WangKey Laboratory of Pathobiology, Ministry of Education, Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Jing SuKey Laboratory of Pathobiology, Ministry of Education, Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Rui ZhaoDepartment of Urology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China. Electronic address: zhaor@jlu.edu.cn.
Yu-Fei GaoDepartment of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China; Jilin Province Neuro-Oncology Engineering Laboratory, Changchun, Jilin, China; Jilin Provincial Key Laboratory of Neuro-Oncology, Changchun, Jilin, China. Electronic address: gaoyf@jlu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer metabolic reprogramming is a driver of tumorigenesis and progression. While extensive research has highlighted the roles of metabolic enzymes and signaling pathways in this process, the mechanisms by which chromatin regulation coordinates the metabolic network at the transcriptional level remain unclear. The SWI/SNF chromatin remodeling complex, a key epigenetic regulator, has recently been shown to modulate multiple tumor metabolic pathways. Metabolic reprogramming induced by mutations in its subunits has garnered increasing attention, but comprehensive reviews on how SWI/SNF-mediated chromatin remodeling governs this process are limited. This paper examines how the SWI/SNF complex regulates metabolic gene transcription by positioning promoters and enhancer regions, guided by transcription factors, and remodeling nucleosome structures. It further discusses its role in regulating glycolysis, the tricarboxylic acid cycle, oxidative phosphorylation, lipid metabolism, and the coupling of carbon-nitrogen metabolism between amino acids and glucose-lipid metabolism. Focusing on subunit mutations such as ARID1A, SMARCA4, and PBRM1, this paper explores their impact on metabolic adaptation, offering insights for identifying therapeutic targets. Based on these findings, a combination intervention strategy targeting the protein levels of glutaminase 1, oxidative phosphorylation (complex I), glutamine transport, and glycolysis is proposed. By integrating SWI/SNF complex status and metabolic phenotypes, a therapeutic framework is developed that balances metabolic compensation blockade and enhanced cell death sensitivity, providing a more precise treatment strategy for metabolism-dependent tumors.

Indexed as

Chromosomal Proteins, Non-HistoneNeoplasmsTranscription FactorsAnimalsChromatin Assembly and DisassemblyGlycolysisHumansMetabolic ReprogrammingChromosomal Proteins, Non-HistoneTranscription Factorscancer metabolic reprogrammingepigenetic regulationglutamine metabolismglycolysisoxidative phosphorylationSWI/SNF complex

Identifiers

PMID41791709
PMCPMC13066803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.